I have not listened to the presentation but i found this about the presentation:
[Shares of Sarepta Therapeutics (SRPT) gained more than 5 percent on the day following Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) including in-depth information in regards to Sarepta’s treatment for Duchenne Muscular Dystrophy in an online slide presentation, through which Vertex describes how Sarepta’s Eteplirsen treatment works. Vertex added that the drug has “demonstrated a broadly favorable safety and tolerability profile and restoration of dystrophin protein expression.”}
To those who listened -- in what context did vrtx bring up the Sarepta drug? Thanks.
so it's safe (Ph I) but it's too early to say it has efficacy for vrtx to buy out srpt. They are saying 100-160 a share. It's now 30 a share and 750MM in MC. that will be 2.1-3.8B or so buyout. VRTX can't afford that. I hope they don't do something stupid.